On January 4, 2022 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that the Company’s leadership will participate in three upcoming, virtual investor conferences in January 2022 (Press release, Nanobiotix, JAN 4, 2022, View Source [SID1234598127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details:

Oddo BHF Forum 2022
Date: January 6-11, 2022
Format: Virtual one-on-one meetings with investors

H.C. Wainwright Bioconnect Conference
Date: January 10-13, 2022
Format: Corporate presentation
Time: Presentation available starting January 10, 2022 at 7:00 AM (EST) / 1:00 PM (CET)

Biotech Showcase 2022
Date: January 17-19, 2022
Format: Corporate presentation and virtual one-on-one meetings with investors
Time: Presentation available starting at 8:00 AM (PT) / 5:00 PM (CET) on January 10, 2022

The presentations will be accessible on the Events section of the company’s website at www.nanobiotix.com.

On January 4, 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that Robert M. Davis, chief executive officer and president, Dr. Dean Y. Li, president, Merck Research Laboratories, are scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Jan. 10, 2022 at 5:15 p.m. ET (Press release, Merck & Co, JAN 4, 2022, View Source [SID1234598126]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at View Source

On January 4, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, reported that the Chief Executive Officer of Boundless Bio, Zachary Hornby, will present at the 40th Annual J.P. Morgan Healthcare Conference which will take place virtually (Press release, Boundless Bio, JAN 4, 2022, View Source [SID1234598125]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, January 11, 2022
Time: 2:00 PM – 2:25 PM EST

On January 4, 2022 Median Technologies (Paris:ALMDT) (ALMDT:PA), reported the publication date for its 2021 results (Press release, MEDIAN Technologies, JAN 4, 2022, View Source [SID1234598122]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Publication

Date

2021 results

April 26, 2022*

*Distribution after the close of trading

On January 4, 2022 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, reported that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET (Press release, Rocket Pharmaceuticals, JAN 4, 2022, View Source [SID1234598120]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available under "Events" in the Investors section of the Company’s website a